Abstract Library

#3042 The Use of Total Parenteral Nutrition in a Series of Patients with Neuroendocrine Tumours in United Kingdom and the Netherlands

Introduction: There are controversies about the use of total parental nutrition (TPN) in patients with cancer. Currently data regarding TPN use in patients with neuroendocrine tumours (NETs) are lacking.

Conference: 17th Annual ENETSConcerence (2020)

Presenting Author: Clement D

Authors: Clement D, Naghibi M, Khan M, Tesselaar M, Verbeek W,

Keywords: total parenteral nutrition, short bowel syndrome, inoperable small bowel obstruction, neuroendocrine tumour,

#2977 Predicting Survival in Patients with a Neuroendocrine Tumor of the Small Intestine (SI-NET)

Introduction: SI-NET comprise the largest group of neuroendocrine tumors. Because of their heterogeneity, predicting survival has proven challenging. A nomogram (NG) to assess SI-NET disease specific survival (DSS) has been developed in 2010 by Modlin, et al. based on analysis of retrospective data from the Surveillance, Epidemiology and End Results (SEER) database.

Conference: 17th Annual ENETSConcerence (2020)

Presenting Author:

Authors: Levy S, van Veenendaal L, Korse C, Verbeek W, Vriens M,

Keywords: SI-NET, Nomogram, Survival,

#2252 Safety and Efficacy of TAE and SIRT in NET Patients

Introduction: Transarterial embolization (TAE) and Selective Internal Radiation Therapy (SIRT) are used for treating patients with liver metastases of a neuroendocrine tumour (NET). However, the safety and effectiveness of TAE and SIRT have scarcely been compared.

Conference: 15th Annual ENETSConcerence (2018)

Presenting Author:

Authors: Van Veenendaal L, Braat A, Meier M, Samsom K, Verbeek W,

Keywords: neuroendocrine tumor, liver metastases, therapy, radioembolization, transarterial embolization, safety, efficacy,

#1881 A Gene Expression-Based Nomogram Predicts Progression Free Survival in Small Bowel NETs

Introduction: Nomograms are predictive tools that help prognosticate. A survival nomogram has been validated for small bowel NETs. A circulating NET specific 51gene signature – the NETest – has efficacy (~95%) as a predictor of progression free survival (PFS).

Conference: 14th Annual ENETSConcerence (2017)

Presenting Author: Kidd M

Authors: Kidd M, Tesselaar M, Korse T, Verbeek W, Drozdov I,

Keywords: Nomogram, prognosis, NETest, PFS, grade, biomarker,

#1485 Validation of a Blood Neuroendocrine Tumor Gene Signature, the NETest, in a Netherlands NET Cohort

Introduction: The CgA has limitations as a monoanalyte biomarker. The introduction of a PCR-based multi-analyte analysis of 51 genes (NETest) has been proposed as more accurate.

Conference: 13th Annual ENETSConcerence (2016)

Presenting Author:

Authors: Tesselaar M, Korse T, Kidd M, Verbeek W, Drozdov I,

Keywords: NETest, CgA, PCR, progressive disease,